Abstract
There is evidence that interferon (IFN) depresses antipyrine and theophylline clearances, thus impairing the drug-metabolizing activity (DMA), whereas ursodeoxycholic acid (UDCA) treatment is associated with controversial findings regarding changes in quantitative liver function tests (LFTs). IFN (Intron A, 6 million units (MU) tiw), a membrane-stabilizing agent — UDCA (Deursil, 600 mg/day) and a new formulation of a free-radical scavenger — silibinin ß cyclodextrin (IBI/S, 135 mg/day) were given to a total of 32 patients with chronic liver disease for 6 months. Liver function, as assessed by routine LFTs and the formation of monoethylglycinexylidide (MEGX) from lidocaine (1 mg/kg iv), was evaluated before and after treatment. For comparison, LFTs and MEGX were also estimated in 10 matched patients with chronic liver disease who received no therapy for 6 months. In the IFN-treated patients the 45-min MEGX values (normal value = 79.1 ± 3.3 ng/ml) were 58.2 ±4.9 at time 0 and increased by 20% during treatment (69.8 ± 5.0); mean ALT levels decreased from 173 ± 20 U/L at time 0 to 98 ± 22 after treatment (p <0.02); AST decreased by 27% whereas γ-GT levels did not vary significantly. MEGX values were virtually unchanged during UDCA and IBI/S administration (respectively, 45.5±5.2 and 53.7±7.6 at entry vs. 47.7±6.3 and 57.4±5.7 at month 6) whereas transaminase levels decreased by 16–30% after UDCA treatment and by 9–19% after IBI/S treatment. Moreover, UDCA and IBI/S caused a 36% and a 24% reduction of γ-GT levels, respectively. In the control group, MEGX values remained stable throughout the 6-month period and so did transaminase and γ-GT levels. Moreover, no correlation was found between the changes in LFTs and the 45-min MEGX values in any of the groups studied. Thus, in patients with chronic liver disease, a 6 months’ treatment with different cytoprotective agents was associated with an improvement in the common markers of liver function but with no significant changes in MEGX formation. These results suggest a lack of interference of tested drugs with DMA and favour the association of various cytoprotective agents with improved treatment outcome.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsPreview
Unable to display preview. Download preview PDF.
References
Poupon R, Poupon RE, Calmous Y et al. Is ursodeoxycholic acid an effective treatment for primary biliary cirrhosis? Lancet. 1987;11:834–6.
Cotting J, Lentze MJ, Reichen J. Effects of ursodeoxycholic acid treatment on nutrition and liver function in patients with cystic fibrosis and longstanding cholestasis. Gut. 1990;31:918–21.
Podda M, Ghezzi C, Battezzati PM et al. Ursodeoxycholic acid, taurine or a combination of the two for chronic hepatitis. Gastroenterology. 1990;98:1044–50.
Plevris JN, Hayes PC, Bouchier IAD. Ursodeoxycholic acid in the treatment of alcoholic liver disease. Eur J Gastroenterol Hepatol. 1991;3:653–6.
Poupon RE, Poupon R, Balkau B and the UDCA—PBC Study Group. Ursodiol for the long-term treatment of primary biliary cirrhosis. N Engl J Med. 1994;330:1342–7.
Beccarello A, Lirussi F, Bortolato L et al. Effect of ursodeoxycholic acid (UDCA) and its taurine-conjugate (TUDCA) in HCV-related and unrelated cirrhosis. Gut. 1994;35(suppl 5):A153.
Lirussi F, Nassuato G, Orlando R et al. Treatment of active cirrhosis with ursodeoxycholic acid and a free radical scavenger: a two year prospective study. Med Sci Res. 1995;23:31–3.
Ferenci P, Dragosic B, Dittrich H et al. Randomized controlled trial of silymarin treatment in patients with cirrhosis of the liver. J Hepatol. 1989;9:105–13.
Meister A. New developments in glutathione metabolism and their potential application in therapy. Hepatology. 1984;4:739–42.
Frezza M, Surrenti C, Marzillo G et al. Oral S-adenosyl-Lmethionine in the symptomatic treatment of intrahepatic cholestasis: a double-blind, placebo controlled study. Gastroenterology. 1990;99:211–15.
Tinè F, Magrin S, Craxi A et al. Interferon for non-A non-B chronic hepatitis. A meta-analysis of randomised clinical trials. J Hepatol. 1991;13:192–9.
Chemello L, Alberti A, Rose K et al. Hepatitis C serotype and response to interferon therapy. N Engl J Med. 1994;330:143.
Lampertico P, Rumi MG, Romeo R et al. A multicentre randomized trial of recombinant interferonalpha-2b in patients with acute transfusion-associated hepatitis C. Hepatology. 1994;19:19–22.
Booth JCL, Brown JL, Thomas HC. The management of chronic hepatitis C virus infection. Gut. 1995;37:449–54.
Di Bisceglie AM, Shindo M, Fong TL et al. A pilot study of ribavirin therapy for chronic hepatitis C. Hepatology. 1992;16:649–54.
Kakumu S, Yoshioka K, Wakita T et al. A pilot study of ribavirin and interferon beta for the treatment of chronic hepatitis C. Gastroenterology. 1993;105:507–12.
Angelico M, Gandin C, Pescarmona E et al. Recombinant interferon-a and ursodeoxycholic acid vs interferon-a alone in the treatment of chronic hepatitis C: a randomized clinical trial with long-term follow-up. Am J Gastroenterol. 1995;90:263–9.
Boucher E, Jouanolle H, Andre P et al. Interferon and ursodeoxycholic acid combined therapy in the treatment of chronic viral C hepatitis: results from a controlled randomized trial in 80 patients. Hepatology. 1995;21:322–7.
Beloqui O, Prieto J, Suarez M et al. N-Acetyl cysteine enhances the response to interferon-alfa in chronic hepatitis C: A pilot study. J Interferon Res. 1993;13:279–82.
Bircher J. Quantitative assessment of deranged hepatic function: A missed opportunity? Semin Liv Dis. 1983;3:275–84.
Oellerich M, Raude E. Monoethylglycinexylidide formation kinetics: a novel approach to assessment of liver function. J Clin Chem Clin Biochem. 1987;25:845–53.
Reichen J, Widmer T, Cotting J. Accurate prediction of death by serial determination of galactose elimination capacity in primary biliary cirrhosis: a comparison with the Mayo model. Hepatology. 1991;14:504–9.
Oellerich M, Burdelski M, Ringe B et al. Lignocaine metabolite formation as a measure of pre-transplant liver function. Lancet. 1989;i:640–2.
Leuschner U, Fischer H, Kurtz W et al. Ursodeoxycholic acid in primary biliary cirrhosis: results of a controlled double-blind trial. Gastroenterology. 1989;97:1268–74.
Lotterer E, Stiehl A, Raedsch R et al. Ursodeoxycholic acid in primary biliary cirrhosis: no evidence for toxicity in the stages Ito III. J Hepatol. 1990;10:284–90.
Lirussi F, Okolicsanyi L. Cytoprotection with ursodeoxycholic acid: effect in chronic non-cholestatic and chronic cholestatic liver disease. Ital J Gastroenterol. 1992;24:31–5.
Williams SJ, Farrel GC. Inhibition of antipyrine metabolism by interferon. Br J Clin Pharmacol. 1986;22:610–12.
Williams SJ, Baird-Lambert JA, Farrel GC. Inhibition of theophylline metabolism by interferon. Lancet. 1987;ii:939–41.
Okuno H, Kitao Y, Takasu M et al. Depression of drug metabolizing activity in the human liver by interferon-α. Eur J Clin Pharmacol. 1990;39:365–7.
Okuno H, Takasu M, Kano H et al. Depression of drug-metabolizing activity in the human liver by interferon-ß. Hepatology. 1993;17:65–9.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1997 Springer Science+Business Media Dordrecht
About this chapter
Cite this chapter
Beccarello, A., Bortolato, L., Paleari, C., Triches, C., Awasum, M., Lirussi, F. (1997). Treatment of Chronic Liver Disease. Do Cytoprotective Agents Interfere with Drug-Metabolizing Activity?. In: Mózsik, G., Nagy, L., Pár, A., Rainsford, K.D. (eds) Cell Injury and Protection in the Gastrointestinal Tract. Springer, Dordrecht. https://doi.org/10.1007/978-94-011-5392-8_27
Download citation
DOI: https://doi.org/10.1007/978-94-011-5392-8_27
Publisher Name: Springer, Dordrecht
Print ISBN: 978-94-010-6268-8
Online ISBN: 978-94-011-5392-8
eBook Packages: Springer Book Archive